BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025

Reuters

2025/09/02

<a href="https://laohu8.com/S/BBIO">BridgeBio Pharma</a> to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025

BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520679-en) on September 02, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564801581"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564801581\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564801581?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564801581","market":"fut","top_or_hot":-1,"title":"BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520679-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-02 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520679-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL8D61ww:1","article_id":"2564801581","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564801581","pubTimestamp":1756812641,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025. BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research  Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and tim","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BBIO":"BridgeBio Pharma, Inc.","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4505":"高瓴资本持仓","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"BridgeBio Pharma将在2025年ASBMR年会上展示Encaleret治疗术后甲状旁腺功能减退症的有希望的2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BBIO":0.9},"content_text":"BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025\n    \n\n        BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520679-en) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}